Literature DB >> 3732895

Transit of pharmaceutical dosage forms through the small intestine.

S S Davis, J G Hardy, J W Fara.   

Abstract

The gastrointestinal transit of pharmaceutical dosage forms has been measured in 201 studies in normal subjects using gamma scintigraphy. Solutions, small pellets, and single units (matrix tablets and osmotic pumps) were administered with different amounts of food in the stomach, ranging from fasted state to heavy breakfast. Gastric emptying was affected by the nature of the dosage form and the presence of food in the stomach. Solutions and pellets were emptied even when the stomach was in the digestive mode, while single units were retained for long periods of time, depending on the size of the meal. In contrast, measured intestinal transit times were independent of the dosage form and fed state. The small intestinal transit time of about three hours (mean +/- 1 h SEM) has implications for the design of dosage forms for the sustained release of drugs in specific positions in the gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3732895      PMCID: PMC1433369          DOI: 10.1136/gut.27.8.886

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  13 in total

1.  Death from sustained release morphine sulphate.

Authors:  D Vere
Journal:  Lancet       Date:  1984-06-30       Impact factor: 79.321

2.  Scintigraphic determination of small intestinal transit time: comparison with the hydrogen breath technique.

Authors:  V J Caride; E K Prokop; F J Troncale; W Buddoura; K Winchenbach; R W McCallum
Journal:  Gastroenterology       Date:  1984-04       Impact factor: 22.682

3.  Measurement of intestinal progression of a meal and its residues in normal subjects and patients with functional diarrhoea by a dual isotope technique.

Authors:  R Jian; Y Najean; J J Bernier
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

4.  Validity of the geometric mean correction in the quantification of whole bowel transit.

Authors:  J G Hardy; A C Perkins
Journal:  Nucl Med Commun       Date:  1985-04       Impact factor: 1.690

5.  Relationship of motility to flow of contents in the human small intestine.

Authors:  P Kerlin; A Zinsmeister; S Phillips
Journal:  Gastroenterology       Date:  1982-04       Impact factor: 22.682

6.  Gastric emptying as a determinant of the oral glucose tolerance test.

Authors:  D G Thompson; D L Wingate; M Thomas; D Harrison
Journal:  Gastroenterology       Date:  1982-01       Impact factor: 22.682

7.  Is the transit time of a meal through the small intestine related to the rate at which it leaves the stomach?

Authors:  N W Read; J Cammack; C Edwards; A M Holgate; P A Cann; C Brown
Journal:  Gut       Date:  1982-10       Impact factor: 23.059

8.  The effect of specific gravity and eating on gastric emptying of slow-release capsules.

Authors:  S A Müller-Lissner; A L Blum
Journal:  N Engl J Med       Date:  1981-05-28       Impact factor: 91.245

9.  Transit of a meal through the stomach, small intestine, and colon in normal subjects and its role in the pathogenesis of diarrhea.

Authors:  N W Read; C A Miles; D Fisher; A M Holgate; N D Kime; M A Mitchell; A M Reeve; T B Roche; M Walker
Journal:  Gastroenterology       Date:  1980-12       Impact factor: 22.682

10.  Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns.

Authors:  P A Cann; N W Read; C Brown; N Hobson; C D Holdsworth
Journal:  Gut       Date:  1983-05       Impact factor: 23.059

View more
  137 in total

Review 1.  Bioadhesion: new possibilities for drug administration?

Authors:  J Woodley
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Influence of drug release properties of conventional solid dosage forms on the systemic exposure of highly soluble drugs.

Authors:  L X Yu; C D Ellison; D P Conner; L J Lesko; A S Hussain
Journal:  AAPS PharmSci       Date:  2001

3.  The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities.

Authors:  L C Kaus; W R Gillespie; A S Hussain; G L Amidon
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

Review 4.  Gamma scintigraphy in the evaluation of pharmaceutical dosage forms.

Authors:  S S Davis; J G Hardy; S P Newman; I R Wilding
Journal:  Eur J Nucl Med       Date:  1992

5.  Linear delivery of verapamil via nanofibrous sheet-based system.

Authors:  Ji Eun Lee; Chun Gwon Park; Byeong Moo An; Myung Hun Kim; Min Park; Seung Ho Lee; Young Bin Choy
Journal:  Pharm Res       Date:  2012-02-14       Impact factor: 4.200

6.  A semi-mechanistic modeling strategy to link in vitro and in vivo drug release for modified release formulations.

Authors:  Martin Bergstrand; Erik Söderlind; Ulf G Eriksson; Werner Weitschies; Mats O Karlsson
Journal:  Pharm Res       Date:  2011-09-27       Impact factor: 4.200

7.  Optimization of LY545694 tosylate controlled release tablets through pharmacoscintigraphy.

Authors:  Evelyn D Lobo; Mark D Argentine; David C Sperry; Alyson Connor; John McDermott; Lloyd Stevens; Ahmad Almaya
Journal:  Pharm Res       Date:  2012-06-14       Impact factor: 4.200

8.  Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects.

Authors:  A J Coupe; S S Davis; I R Wilding
Journal:  Pharm Res       Date:  1991-03       Impact factor: 4.200

Review 9.  Biomagnetic methods: technologies applied to pharmaceutical research.

Authors:  Luciana A Corá; Madileine F Américo; Ricardo B Oliveira; Cristina H R Serra; Oswaldo Baffa; Raul C Evangelista; Giselle F Oliveira; José Ricardo Aruda Miranda
Journal:  Pharm Res       Date:  2010-10-15       Impact factor: 4.200

10.  Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole.

Authors:  T Zimmermann; R A Yeates; H Laufen; G Pfaff; A Wildfeuer
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.